News

Trading Update Confirmation of Preferred Provider Status
Trading Update Confirmation of Preferred Provider Status
November 6, 2018

The Company is pleased to announce that recognised revenues from services during the third quarter were the strongest this year and early evidence of a characteristically stronger fourth quarter suggests that the value of committed work orders in 2018 should be more than double that achieved in 2017.  However, overall performance remains behind plan and full year service revenues will likely be in line with the previous year reflecting the time taken to execute orders.  Sales and marketing activities are prominent despite a limited budget, with high volumes of customer calls and requests for quotations as well as exhibitions in Germany, US, Denmark, UK and Spain during the fourth quarter.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
October 12, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on the 9 and 10 October 2018 it purchased 100,000 and 180,790 Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.66p per Ordinary Share (the “Purchase”).  Following the Purchase, Vulpes has a total direct and indirect interest in 61,132,777 equivalent to 20.71% of Proteome Sciences' total issued share capital.

Director/PDMR shareholding
Director/PDMR shareholding
October 9, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 9 October 2018 that on the 5 and 8 October 2018 it purchased 54,000 and 460,899  Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,851,987 equivalent to 20.62% of Proteome Sciences' total issued share capital.

 

Block Listing Interim Review
Block Listing Interim Review
October 8, 2018

Block Admission Return

Director/PDMR Shareholding
Director/PDMR Shareholding
October 4, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 2 October 2018 that it purchased 20,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,337,088 equivalent to 20.44% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
October 1, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 1 October 2018 that on 27 and 28 September 2018, it purchased 81 and 910,608 Ordinary Shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,317,088 equivalent to 20.43% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 21, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 21 September 2018, it purchased 75,520 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 59,406,399 equivalent to 20.13% of Proteome Sciences' total issued share capital.

Director/PDMR shareholding
Director/PDMR shareholding
September 12, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 11 September 2018, it purchased 601,582 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 59,330,879 equivalent to 20.01% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 7, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 469,866 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 58,729,297 equivalent to 19.89% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
August 14, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 500,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 58,259,431 equivalent to 19.74% of Proteome Sciences' total issued share capital.